BioMaxima Statistics

Total Valuation

BioMaxima has a market cap or net worth of PLN 51.58 million. The enterprise value is 62.82 million.

Market Cap	51.58M
Enterprise Value	62.82M

Important Dates

The next estimated earnings date is Wednesday, April 30, 2025.

Earnings Date	Apr 30, 2025
Ex-Dividend Date	n/a

Share Statistics

BioMaxima has 4.19 million shares outstanding. The number of shares has decreased by -4.18% in one year.

Current Share Class	n/a
Shares Outstanding	4.19M
Shares Change (YoY)	-4.18%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	22.38%
Owned by Institutions (%)	n/a
Float	2.69M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.06
PB Ratio	1.11
P/TBV Ratio	1.11
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 26.89, with an EV/FCF ratio of -12.62.

EV / Earnings	-138.38
EV / Sales	1.28
EV / EBITDA	26.89
EV / EBIT	n/a
EV / FCF	-12.62

Financial Position

The company has a current ratio of 1.83, with a Debt / Equity ratio of 0.26.

Current Ratio	1.83
Quick Ratio	0.78
Debt / Equity	0.26
Debt / EBITDA	5.24
Debt / FCF	-2.46
Interest Coverage	-0.89

Financial Efficiency

Return on equity (ROE) is -0.93% and return on invested capital (ROIC) is -0.67%.

Return on Equity (ROE)	-0.93%
Return on Assets (ROA)	-0.54%
Return on Invested Capital (ROIC)	-0.67%
Return on Capital Employed (ROCE)	-1.03%
Revenue Per Employee	425,861
Profits Per Employee	-3,948
Employee Count	115
Asset Turnover	0.67
Inventory Turnover	1.92

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -19.57% in the last 52 weeks. The beta is -2.40, so BioMaxima's price volatility has been lower than the market average.

Beta (5Y)	-2.40
52-Week Price Change	-19.57%
50-Day Moving Average	12.25
200-Day Moving Average	14.66
Relative Strength Index (RSI)	56.83
Average Volume (20 Days)	7,120

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, BioMaxima had revenue of PLN 48.97 million and -454,000 in losses. Loss per share was -0.11.

Revenue	48.97M
Gross Profit	22.21M
Operating Income	-634,000
Pretax Income	-852,000
Net Income	-454,000
EBITDA	2.19M
EBIT	-634,000
Loss Per Share	-0.11

Full Income Statement

Balance Sheet

The company has 1.00 million in cash and 12.25 million in debt, giving a net cash position of -11.25 million or -2.68 per share.

Cash & Cash Equivalents	1.00M
Total Debt	12.25M
Net Cash	-11.25M
Net Cash Per Share	-2.68
Equity (Book Value)	46.60M
Book Value Per Share	11.11
Working Capital	10.73M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 4.80 million and capital expenditures -9.77 million, giving a free cash flow of -4.98 million.

Operating Cash Flow	4.80M
Capital Expenditures	-9.77M
Free Cash Flow	-4.98M
FCF Per Share	-1.19

Full Cash Flow Statement

Margins

Gross margin is 45.35%, with operating and profit margins of -1.29% and -0.93%.

Gross Margin	45.35%
Operating Margin	-1.29%
Pretax Margin	-1.74%
Profit Margin	-0.93%
EBITDA Margin	4.46%
EBIT Margin	-1.29%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 0.39, which amounts to a dividend yield of 3.17%.

Dividend Per Share	0.39
Dividend Yield	3.17%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	4.18%
Shareholder Yield	7.35%
Earnings Yield	-0.88%
FCF Yield	-9.65%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

BioMaxima has an Altman Z-Score of 2.95. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.95
Piotroski F-Score	n/a